Simcere Pharmaceutical Group (HKEX: 2096) has secured exclusive commercialization rights in Greater China for RB0026 (库莱韦拜单抗), a long-acting, fully human RSV monoclonal antibody developed by Ruiyang (Shandong) Biopharmaceutical Co., Ltd. The deal gives Simcere a China-originated asset at an advanced regulatory stage, with its marketing authorization application already accepted by China's Center for Drug Evaluation (CDE) and placed under priority review. Financial terms were not disclosed.
RB0026 targets the RSV fusion protein (F protein) and incorporates half-life optimization designed to extend its duration of action. Ruiyang is developing the antibody to provide protection to infants across an entire RSV season following a single injection. A Phase III trial in children aged one to two years is ongoing to expand the product's target age range.
If approved, RB0026 could become China's first domestically developed long-acting RSV preventive antibody, according to the companies, providing a local competitor to Sanofi and AstraZeneca's Beyfortus (nirsevimab). Both antibodies target the RSV F protein and are designed to provide protection across an RSV season following a single administration. Beyfortus received NMPA approval in December 2023 and launched in China in January 2024, meaning RB0026 would enter an established therapeutic category currently dominated by an imported product.
The transaction is structured as a commercialization license rather than a co-development arrangement. Ruiyang retains responsibility for ongoing clinical development, while Simcere takes responsibility for commercialization and market access across Greater China. The arrangement allows Ruiyang to leverage the larger drugmaker's established anti-infectives commercial infrastructure as RB0026 approaches a potential launch.